These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 25136597

  • 1. Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.
    Baumann Kreuziger LM, Keenan JC, Morton CT, Dries DJ.
    Biomed Res Int; 2014; 2014():583794. PubMed ID: 25136597
    [Abstract] [Full Text] [Related]

  • 2. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS.
    Am J Health Syst Pharm; 2013 May 15; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [Abstract] [Full Text] [Related]

  • 3. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun 15; 22(139):155-9. PubMed ID: 23866358
    [Abstract] [Full Text] [Related]

  • 4. How I treat target-specific oral anticoagulant-associated bleeding.
    Siegal DM, Garcia DA, Crowther MA.
    Blood; 2014 Feb 20; 123(8):1152-8. PubMed ID: 24385535
    [Abstract] [Full Text] [Related]

  • 5. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T, Böhm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Röther J, Schellinger PD, Spannagl M, Veltkamp R.
    Clin Res Cardiol; 2013 Jun 20; 102(6):399-412. PubMed ID: 23669868
    [Abstract] [Full Text] [Related]

  • 6. Bleeding and antidotes in new oral anticoagulants.
    Majeed A, Schulman S.
    Best Pract Res Clin Haematol; 2013 Jun 20; 26(2):191-202. PubMed ID: 23953907
    [Abstract] [Full Text] [Related]

  • 7. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.
    Circ Cardiovasc Qual Outcomes; 2012 Jul 01; 5(4):480-6. PubMed ID: 22787066
    [Abstract] [Full Text] [Related]

  • 8. Strategies for urgent reversal of target-specific oral anticoagulants.
    Davis EM, Uhlmeyer EM, Schmidt DP, Schardt GL.
    Hosp Pract (1995); 2014 Dec 01; 42(5):108-25. PubMed ID: 25485923
    [Abstract] [Full Text] [Related]

  • 9. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
    Ragni MV.
    Hematology Am Soc Hematol Educ Program; 2013 Dec 01; 2013():44-51. PubMed ID: 24319161
    [Abstract] [Full Text] [Related]

  • 10. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW, Barillari G.
    J Clin Pharm Ther; 2014 Apr 01; 39(2):118-35. PubMed ID: 24383983
    [Abstract] [Full Text] [Related]

  • 11. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S, Ansell J.
    Thromb Haemost; 2012 Sep 01; 108(3):476-84. PubMed ID: 22740145
    [Abstract] [Full Text] [Related]

  • 12. Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
    Levy JH.
    Clin Lab Med; 2014 Sep 01; 34(3):443-52. PubMed ID: 25168936
    [Abstract] [Full Text] [Related]

  • 13. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
    Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.
    Am J Cardiol; 2012 Aug 01; 110(3):453-60. PubMed ID: 22537354
    [Abstract] [Full Text] [Related]

  • 14. [Management of direct action oral anticoagulants in the peri-operative period and invasive techniques].
    Llau JV, Ferrandis R, Castillo J, de Andrés J, Gomar C, Gómez-Luque A, Hidalgo F, Torres LM, participantes en el Foro de Consenso de la ESRA-España sobre «Fármacos que alteran la hemostasia».
    Rev Esp Anestesiol Reanim; 2012 Aug 01; 59(6):321-30. PubMed ID: 22633209
    [Abstract] [Full Text] [Related]

  • 15. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Fawole A, Daw HA, Crowther MA.
    Cleve Clin J Med; 2013 Jul 01; 80(7):443-51. PubMed ID: 23821689
    [Abstract] [Full Text] [Related]

  • 16. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
    Int Angiol; 2012 Aug 01; 31(4):330-9. PubMed ID: 22801398
    [Abstract] [Full Text] [Related]

  • 17. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G, Alsaleh K, Wu C, Mcmurtry MS.
    Int Angiol; 2014 Aug 01; 33(4):301-8. PubMed ID: 25056161
    [Abstract] [Full Text] [Related]

  • 18. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
    Lazo-Langner A, Lang ES, Douketis J.
    Crit Care; 2013 Jun 17; 17(3):230. PubMed ID: 23806169
    [Abstract] [Full Text] [Related]

  • 19. Newer clinically available antithrombotics and their antidotes.
    Lévy S.
    J Interv Card Electrophysiol; 2014 Sep 17; 40(3):269-75. PubMed ID: 24934756
    [Abstract] [Full Text] [Related]

  • 20. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
    Fenger-Eriksen C, Münster AM, Grove EL.
    Acta Anaesthesiol Scand; 2014 Jul 17; 58(6):651-9. PubMed ID: 24716468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.